

Rachel E Rau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9142524/publications.pdf>

Version: 2024-02-01

80
papers

1,817
citations

394286

19
h-index

276775

41
g-index

84
all docs

84
docs citations

84
times ranked

3450
citing authors

#	ARTICLE	IF	CITATIONS
1	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. <i>Haematologica</i> , 2022, 107, 887-898.	1.7	15
2	Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7033-7033.	0.8	1
3	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	0.8	0
4	Efficacy and safety of intramuscular (IM) recombinant <i>Erwinia</i> asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children's Oncology Group (COG) AALL1931 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7001-7001.	0.8	1
5	An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. <i>Leukemia</i> , 2021, 35, 1777-1781.	3.3	3
6	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	0.8	9
7	Can recombinant technology address asparaginase <i>Erwinia chrysanthemi</i> shortages?. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29169.	0.8	18
8	Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S99-S101.	0.2	0
9	Modeling <i>IKZF1</i> lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. <i>Blood Advances</i> , 2021, 5, 3876-3890.	2.5	6
10	Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4992-5001.	2.5	6
11	A viral cause of APL. <i>Blood</i> , 2021, 138, 1653-1655.	0.6	3
12	Initial Results from a Phase 2/3 Study of Recombinant <i>Erwinia</i> Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to <i>E. coli</i> -Derived Asparaginases. <i>Blood</i> , 2021, 138, 2307-2307.	0.6	4
13	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	0.6	10
14	Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28063.	0.8	9
15	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.	0.8	52
16	Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 1129.	1.3	13
17	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S8-S11.	0.2	3
18	SIRPassing other xenograft murine models?. <i>Blood</i> , 2020, 135, 1612-1614.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	1.2	21
20	The genomics of acute myeloid leukemia in children. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 189-209.	2.7	26
21	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e132-e143.	1.8	15
22	A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7568-TPS7568.	0.8	4
23	Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with <i>KMT2A</i> Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 34-34.	0.6	0
24	Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
25	Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27577.	0.8	11
26	Sustained remission with azacitidine monotherapy and an aberrant precursor B lymphoblast population in juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27905.	0.8	7
27	3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 30-31.	0.3	0
28	Ponatinib use in two pediatric patients with relapsed Ph+ ALL with ABL1 kinase domain mutations. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 514-519.	0.3	2
29	A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. <i>Blood</i> , 2019, 134, 1960-1972.	0.6	38
30	Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning. <i>Cell Stem Cell</i> , 2019, 24, 511-512.	5.2	0
31	Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3789-3789.	0.6	2
32	A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3792-3792.	0.6	0
33	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in <i>Pseudomonas Fluorescens</i> (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to <i>Escherichia coli</i> -Derived Asparaginases. <i>Blood</i> , 2019, 134, 2586-2586.	0.6	0
34	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26873.	0.8	48
35	Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2018, 13, e0197408.	1.1	4
36	A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Pediatric Blood and Cancer</i> , 2018, 65, e27066.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Using genomics to define pediatric blood cancers and inform practice. Hematology American Society of Hematology Education Program, 2018, 2018, 286-300.	0.9	6
38	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. Blood, 2018, 132, 549-549.	0.6	1
39	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.	0.6	5
40	Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget, 2018, 9, 35313-35326.	0.8	6
41	Abstract 145: Pharmacologic inhibition of SIAH2 stabilizes DYRK2 and inhibits survival and self-renewal in chronic myeloid leukemia (CML) leukemic stem cells. , 2018, , .		0
42	Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage. Blood, 2018, 132, 173-173.	0.6	0
43	Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26487.	0.8	10
44	50 Years Ago in The Journal of Pediatrics. Journal of Pediatrics, 2017, 183, 140.	0.9	0
45	CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3. Blood, 2017, 130, 385-386.	0.6	3
46	Klinefelter syndrome and 47, <sc>XYY</sc> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	1.2	4
47	Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology, 2016, 44, 740-744.	0.2	48
48	Beyond KIT in CBF-AML: chromatin and cohesin. Blood, 2016, 127, 2370-2371.	0.6	6
49	DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood, 2016, 128, 971-981.	0.6	107
50	DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell, 2016, 29, 922-934.	7.7	107
51	A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314).. Journal of Clinical Oncology, 2016, 34, 2567-2567.	0.8	1
52	Aberrant Precursor B Lymphoid Blast Population in a Patient with Juvenile Myelomonocytic Leukemia. Blood, 2016, 128, 5557-5557.	0.6	0
53	Leukemia Fusion Gene Detection in the Clinical Molecular Laboratory Using RNA-Based Targeted Next-Generation Sequencing. Blood, 2016, 128, 4074-4074.	0.6	0
54	DNMT3A in haematological malignancies. Nature Reviews Cancer, 2015, 15, 152-165.	12.8	379

#	ARTICLE	IF	CITATIONS
55	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. <i>Blood</i> , 2015, 126, 1312-1312.	0.6	2
56	Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors. <i>Blood</i> , 2015, 126, 1277-1277.	0.6	0
57	A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplasm in Double Knock-in Mice with WT1 and FLT3/ITD Mutations. <i>Blood</i> , 2015, 126, 312-312.	0.6	1
58	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. <i>Experimental Hematology</i> , 2014, 42, 101-113.e5.	0.2	32
59	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. <i>Oncotarget</i> , 2014, 5, 8947-8958.	0.8	51
60	DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 614-614.	0.6	0
61	Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model. <i>Blood</i> , 2014, 124, 3572-3572.	0.6	12
62	Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Chemistry and Biology</i> , 2013, 20, 1352-1363.	6.2	72
63	MLL rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. <i>British Journal of Haematology</i> , 2013, 160, 785-797.	1.2	39
64	Dnmt3a-Deletion Accelerates FLT3-ITD Malignancies In Mice By Hypomethylation Of Enhancer Sites and Activating Stem Cell Programs; Implications For Therapy. <i>Blood</i> , 2013, 122, 595-595.	0.6	1
65	Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Blood</i> , 2013, 122, 171-171.	0.6	0
66	Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis. <i>Blood</i> , 2013, 122, 1269-1269.	0.6	0
67	Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. <i>Blood</i> , 2011, 118, 1410-1410.	0.6	0
68	Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. <i>Blood</i> , 2011, 118, 2437-2437.	0.6	0
69	Fatal Infection Caused by <i>Cupriavidus gilardii</i> in a Child with Aplastic Anemia. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1005-1007.	1.8	39
70	Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. <i>Blood</i> , 2010, 116, 145-145.	0.6	1
71	Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. <i>Hematological Oncology</i> , 2009, 27, 171-181.	0.8	127
72	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. <i>Blood</i> , 2009, 114, 2742-2742.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Triad of Severe Abdominal Pain, Inappropriate Antidiuretic Hormone Secretion, and Disseminated Varicella-Zoster Virus Infection Preceding Cutaneous Manifestations After Hematopoietic Stem Cell Transplantation. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 265-268.	1.1	37
74	The incidence and clinical significance of nucleophosmin mutations in childhood AML. <i>Blood</i> , 2007, 110, 979-985.	0.6	193
75	Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.. <i>Blood</i> , 2006, 108, 221-221.	0.6	1
76	Predictors of Acute Intracranial Pathology Identified by Computerized Tomography in Children with Sickle Cell Disease.. <i>Blood</i> , 2006, 108, 3798-3798.	0.6	0
77	Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. <i>American Journal of Infection Control</i> , 2004, 32, 189-195.	1.1	98
78	Constitutive loss of DNMT3A causes morbid obesity through misregulation of adipogenesis. <i>ELife</i> , 0, 11, .	2.8	12
79	Murine Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
80	Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	22